Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Mudcat who wrote (17608)	3/18/1998 11:52:00 AM
From: dwc	Respond to of 32384

And what do you think is going to drive the price to $30 if not new alliances and positive press releases (that the public can understand)

To: Mudcat who wrote (17608)	3/18/1998 12:31:00 PM
From: Flagrante Delictu	Respond to of 32384

Mudcat, >>...what happens to LGND's share price when these drug cos. start selling all these shares they are accumulating? << If your contention that " even LGND management doesn't believe their stock will go much higher", is true, it would be plausible for them to unload this high priced stock now to the innocent drug cos. & hold onto the money until the stock collapses, & then buy up many more shares at ridiculously low prices than they sold at the current high prices. On the other hand, cock-eyed {IYWPTE} optimists might wonder why pharmaceutical companies were so anxious to buy LGND stock at these prices. At worst, they can probably get a tax loss when they sell at ignominiously low prices. At best, they'll want to share the wine Andy has to deliver to Henry this summer on the penetration {IYWPTE} of 30. Bernie

To: Mudcat who wrote (17608)	3/18/1998 12:38:00 PM
From: Machaon	Read Replies (1) \| Respond to of 32384

<< I also do not see why this leptin deal is a good deal for LGND >> We need to see more details from the deal. From today's article: <=================================================================== The agreement also *provides for cash payments* if subsequent milestones are met. Under the new agreement, SB will obtain exclusive worldwide rights to products resulting from the obesity collaboration and *has agreed to make milestone payments to Ligand* as compounds progress through preclinical and clinical development, and royalty payments on sales, if products result from the research. ====================================================================>